CelLBxHealth (FRA:DWV) Other Stockholders Equity: €-1.19 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is CelLBxHealth Other Stockholders Equity?

CelLBxHealth FRA:DWV +3.23% Other Stockholders Equity is €-1.19 Mil as of Jun. 2026. The stock has 6 warning signs investors should review.

CelLBxHealth's Other Stockholders Equity for the quarter that ended in Jun. 2026 was €-1.19 Mil.

CelLBxHealth's quarterly Other Stockholders Equity declined from Jun. 2025 (€3.81 Mil) to Dec. 2025 (€1.58 Mil) and declined from Dec. 2025 (€1.58 Mil) to Jun. 2026 (€-1.19 Mil).

CelLBxHealth's annual Other Stockholders Equity declined from Dec. 2023 (€3.82 Mil) to Dec. 2024 (€1.16 Mil) but then increased from Dec. 2024 (€1.16 Mil) to Dec. 2025 (€1.58 Mil).

CelLBxHealth Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for CelLBxHealth's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CelLBxHealth Other Stockholders Equity Chart

CelLBxHealth Annual Data
Trend Apr16 Apr17 Apr18 Apr19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.43 2.06 3.82 1.16 1.58

CelLBxHealth Semi-Annual Data
Oct16 Apr17 Oct17 Apr18 Oct18 Apr19 Oct19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.57 1.16 3.81 1.58 -1.19

CelLBxHealth Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of €-1.19 Mil mean?
CelLBxHealth (FRA:DWV) has a Other Stockholders Equity of €-1.19 Mil as of Jun. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on CelLBxHealth and its competitors.
Is CelLBxHealth's Other Stockholders Equity too high?
CelLBxHealth's current Other Stockholders Equity is €-1.19 Mil.
How does CelLBxHealth's Other Stockholders Equity compare to TMO and DHR?
CelLBxHealth's Other Stockholders Equity of €-1.19 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Medical Diagnostics & Research company?
A good Other Stockholders Equity depends on the Medical Diagnostics & Research industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on CelLBxHealth and its competitors. CelLBxHealth's current Other Stockholders Equity is €-1.19 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CelLBxHealth stock overvalued right now?
Based on GuruFocus' analysis, CelLBxHealth (FRA:DWV) is currently considered Possible Value Trap. The stock's GF Value™ is €0.04, compared to a current price of €0.02 — trading 60% below its estimated fair value. The current Other Stockholders Equity is €-1.19 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For CelLBxHealth (FRA:DWV), the current Other Stockholders Equity is €-1.19 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CelLBxHealth Business Description

Other Exchanges ANPCF:USACLBX:UK
Address 10 Nugent Road, The Surrey Research Park, Surrey, Guildford, GBR, GU2 7AF
CelLBxHealth PLC is active in the healthcare sector in the United Kingdom. The Company's principal trading activity is undertaken in relation to the development and commercialization of the Parsortix cell separation system, with deployment in liquid biopsy that is non-invasive cancer diagnostics. It is a medical diagnostic company specializing in the development of pioneering products in cancer diagnostics. Its patented Parsortix technology can potentially treat and diagnose various forms of cancer. The Parsortix system can capture and harvest CTCs from patient blood. Its geographical segments include Europe and North America, of which the majority of its revenue is generated from Europe.